secwatch.observer — SEC 8-K summary
======================================

Issuer:     Virpax Pharmaceuticals, Inc. (—)
CIK:        0001708331
Form:       8-K
Filed at:   2023-10-11T23:59:59+00:00
Accession:  0001013762-23-003163
Event type: regulatory
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Virpax gets Nasdaq extension to April 2024 for minimum bid compliance
---------------------------------------------------------------------

- Received 180-day extension from Nasdaq to April 8, 2024 to meet $1.00 minimum bid price.
- Previously failed to regain compliance by Oct 9, 2023 after initial April 10, 2023 notice.
- Must maintain bid price of at least $1.00 for ten consecutive business days to comply.
- Considering options including reverse stock split to maintain Nasdaq listing.
- Stock continues trading on Nasdaq Capital Market under symbol VRPX with no immediate impact.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708331/000101376223003163/0001013762-23-003163-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708331/000101376223003163/ea186627-8k_virpaxpharma.htm
  HTML page:      https://secwatch.observer/filing/0001013762-23-003163

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer